Sex-specific differences in KCC2 localisation and inhibitory synaptic transmission in the rat hippocampus.

Sex differences in the developing brain impact stress-induced epileptogenicity following hyperthermia-induced seizures.

The codification of hazard and its impact on the hazard versus risk controversy.

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn's Disease Defined by a Serum-Based Endoscopic Healing Index.

Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients.

Paraquat pharmacokinetics in primates and extrapolation to humans.

Integration of paraquat pharmacokinetic data across species using PBPK modelling.

Successful liver transplantation in a patient recovered from COVID-19.

A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals.

Metabolomic Profiles in the Brains of Juvenile Steelhead (Oncorhynchus mykiss) Following Bifenthrin Treatment.

Implementing a globally harmonized risk assessment-based approach for regulatory decision-making of crop protection products.

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.